

# Soft Tissue Sarcoma

Advanced or Metastatic

Synovial & Myxoid Liposarcoma

Soft Tissue Sarcoma

2nd Line

Dedifferentiated Liposarcoma and Osteosarcoma

Locally Advanced

Dedifferentiated Liposarcoma

**CCT5031**  
 Phase II  
[NY-ESO-1-Specific \(c259\) T Cells +/- Other Agents in HLA-A2+ w/ NY-ESO-1 &/or LAGE-1a + ST](#)

PI: Ganjoo  
 Sponsor: GlaxoSmithKline

**CCT5033**  
 Phase II  
[ADP-A2M4 SPEAR T Cells in Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma](#)

PI: Ganjoo  
 Adaptimmune

**SARCOMA0054**  
 Phase I/II Open Label Safety, Tolerability and Efficacy Study of ASP0739 as Single Agent and in Combination w/ Pembrolizumab in Advanced Solid Tumors known to Express NY-ESO-1.

PI: Ganjoo  
 Sponsor: Astellas Pharma Global Development, Inc.

**SARCOMA0051**  
 Phase III Study of Milademetan vs Trabectedin in Patients with Dedifferentiated Liposarcoma

PI: Bui  
 Sponsor: Rain Therapeutics, Inc.

**SARCOMA0046**  
 Phase II  
[Envafolimab +/- Ipilimumab in Advanced or Metastatic UP Sarcoma or Myxofibro sarcoma](#)

PI: Ganjoo  
 Sponsor: Traccon Pharmaceuticals

**SARCOMA0053**  
 Phase II  
 Cabozantinib Combined w/ PD-1 & CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma

PI: Ganjoo  
 Washington University

**SARCOMA0055**  
 Phase II  
 ABI-009 in Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes

PI: Ganjoo  
 Aadi Bioscience, Inc.

**SARCOMA0043**  
 Phase I  
[SQ3370 in Advanced Solid Tumors](#)

PI: Bui  
 Sponsor: Shasqi









**SARCOMA0045**  
 Phase II  
[Cytoreductive Surgery & HIPEC w/ Gemcitabine + Chemotherapy w/ Dacarbazine in Uterine Leiomyosarcoma](#)

PI: Ganjoo  
 Stanford

**SARC-024**  
 Phase II  
[Regorafenib in Refractory Liposarcoma, Osteogenic Sarcoma, & Ewing/Ewing-Like Sarcomas](#)

PI: Ganjoo  
 SARC

## KEY

	Pending		Optional Path		Extension Study
	Open for Enrollment		Trial Posting		Immunotherapy
	Observational Study		Enrollment on Hold		